Company History
High Throughput Genomics (HTG) was founded in 1997 with the mission to develop a universal molecular biology-based platform to improve the pharmaceutical drug discovery process. Since that time, HTG has expanded the utility of qNPA™ technology into the fields of gene expression profiling, Translational Medicine and Diagnostic applications and the measurement of miRNA.
Our quantitative Nuclease Protection Assay (qNPA™) Technology is designed to deliver robust and reliable results with a simple, automatable protocol. qNPA technology is ideal for detecting small yet important changes in gene expression levels which other gene expression platforms cannot reliably detect. The unique combination of precision and accuracy with the fast, no RNA extraction protocol provides researchers with a tool ideal for gene expression analysis in moderate to high sample volume research settings using a wide array of sample types.
2009
September
HTG launches its first microarray-based product, the qNPA miRNA Microarray for miRNA expression profiling
March
HTG reaches an agreement with Clinical Reference Laboratories (CRL) to provide qNPA Technology in a CLIA certified lab setting
2008
November
Fred Pollock joins HTG as VP of Corporate Development
August
HTG launches its first miRNA product, the qCustom miRNA ArrayPlate
April
BJ Kerns joins HTG to lead the commercial and diagnostic strategies
March
HTG receives a Phase I SBIR grant for $300k to develop a microfluidics diagnostic qNPA platform to monitor white blood cell response.
January
TJ Johnson joins HTG as CEO and President.
2007
HTG and the University of Arizona Bio5 Center for Chemical Genomics and Translational Research receive $2M seed funding from Science Foundation Arizona.
September
HTG receives a Phase I SBIR grant for $300k to develop a 1600 gene high density qNPA™ array from NIMH.
2005
December
Don Grimm joins HTG’s Board of Directors. Company records its second profitable operating quarter.
September
HTG records its first profitable operating quarter.
July
HTG purchases print and hybridization acceleration IP from Sigma Aldrich.
April
Company completes its “Series B” round of financing.
2004
September
Services agreements reached with Takeda Pharmaceutical Company, Ltd. to support Takeda’s pharmaceutical research.
August
Kirk Collamer assumes positions of company President and CEO.
Bruce Seligmann assumes position of CSO and Chairman of the Board
April
Merck & Co., Inc. licenses HTG’s gene expression assay technology worldwide.
February
National Cancer Institute awards HTG a two-year grant to identify genes for toxicity studies.
2003
August
William Linton, founder of Promega Corporation, joins HTG’s Board of Directors.
2002
November
Third U.S. patent issued
April
Kirk Collamer joins HTG as Chief Financial Officer.
January
Completed “Series A” preferred round of company financing. Purchased Genometrix Universal Array IP and tangible assets. First Omix Imaging System sold and HTS assay contract. Client: Psychiatric Genomics, Inc.
2001
October
First service contract. Client: Signal Research, division of Celgene Corporation
July
HTG introduced its first commercial product, the ArrayPlate™ 96-16.
May
First Generic Array and qNPA patents issued.
March
Completed Founders round of investment.
January
HTG was divested from SIDDCO. Generic Array and quantitative Nuclease Protection Array (qNPA) IP was purchased from NeoGen, Inc.
2000
December
HTG was divested to SIDDCO’s shareholders prior to its sale to Discovery Partners international, Inc. At the time of divestiture, HTG’s intellectual portfolio included license rights to Generic Array and qNPA technology, invented by NeoGen L.L.C.
Bruce Seligmann, founder, assumes President and CEO positions
1997
High Throughput Genomics, Inc, (HTG) was established as a wholly owned subsidiary of Systems Integration Drug Discovery Company (SIDDCO), a privately held combinatorial chemistry company.
